Blueshift Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Blueshift Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,874	Closed	-$253K	–	477
2025 Q3	$253K	Sell	4,874 -6,153	-56%	-$300K	0.08%	345
2025 Q2	$476K	Buy	+11,027	New	+$401K	0.15%	190
2023 Q4	–	Sell	-16,482	Closed	-$435K	–	268
2023 Q3	$435K	Buy	+16,482	New	+$468K	0.26%	111
2022 Q2	–	Sell	-21,830	Closed	-$222K	–	683
2022 Q1	$222K	Buy	+21,830	New	+$224K	0.02%	707

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blueshift Asset Management's BBIO Position: Q4 2025 in Review

Blueshift Asset Management sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 4,874 shares — an estimated $253K sold.

Blueshift Asset Management first reported a position in BBIO in Q1 2022 and held it in 4 quarters. The position peaked at $476K in Q2 2025. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

Blueshift Asset Management reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
Blueshift Asset Management sold 4,874 BridgeBio Pharma shares in Q4 2025, an estimated $253K.
Blueshift Asset Management first reported a position in BridgeBio Pharma in Q1 2022 and held it in 4 quarters.
Blueshift Asset Management's BridgeBio Pharma position peaked at $476K in Q2 2025.
433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Blueshift Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.